UNIT 9.33 A Murine Model of Atypical Antipsychotic-Induced Weight Gain and Metabolic Dysregulation

  1. Roberto Coccurello,
  2. Anna Moles

Published Online: 1 JUL 2010

DOI: 10.1002/0471142301.ns0933s52

Current Protocols in Neuroscience

Current Protocols in Neuroscience

How to Cite

Coccurello, R. and Moles, A. 2010. A Murine Model of Atypical Antipsychotic-Induced Weight Gain and Metabolic Dysregulation. Current Protocols in Neuroscience. 52:9.33:9.33.1–9.33.22.

Author Information

  1. Institute of Neuroscience, National Research Council (C.N.R.), Rome, Italy

Publication History

  1. Published Online: 1 JUL 2010
  2. Published Print: JUL 2010


In comparison with conventional, first-generation antipsychotics (e.g., haloperidol), the administration of atypical antipsychotics (AAPs) has been associated with a higher risk of metabolic derangements, including body weight increase, dysregulation of glucose homeostasis, fat accumulation, and even liability to develop type II diabetes. Since this is a serious clinical problem that may be further exacerbated in overweight schizophrenics, establishing animal models of AAP-induced adverse effects may contribute to clarifying the mechanisms underlying these effects. Here we present three basic protocols by which this problem has been modeled. The three protocols differ in many aspects (routes of administration, extent of the chronic treatment, diets, and dosage regimen), and the pros and cons of each procedure are systematically detailed throughout. It should be noted that several factors (e.g., species, sex, duration, and class of AAPs) could restrict the feasibility of these models, as well as their correspondence to the clinical condition. Curr. Protoc. Neurosci. 52:9.33.1-9.33.22. © 2010 by John Wiley & Sons, Inc.


  • atypical antipsychotic;
  • olanzapine;
  • weight gain;
  • metabolic dysregulation;
  • food intake;
  • high-fat diet